Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02490787 · ClinicalTrials.gov registry record · Phase 1
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
A Phase 1 study of Haemophilia A and Congenital Bleeding Disorder, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 20
- Study locations
NCT02490787: Completed Phase 1 study of Haemophilia A and Congenital Bleeding Disorder, sponsored by Novo Nordisk A/S.
NCT02490787 is a Phase 1 study of Haemophilia A and Congenital Bleeding Disorder that has completed, run by Novo Nordisk A/S. The registered enrollment target is 24 participants, below the 222-participant average among 8 other Haemophilia A trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02490787, a Phase 1 study of Haemophilia A and Congenital Bleeding Disorder, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted globally. The aim of this trial is to investigate safety, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of concizumab administered subcutaneously to haemophilia A subjects.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Concizumab
Study Locations (20)
Other
- Novo Nordisk Investigational Site - Vienna
- Novo Nordisk Investigational Site - Zagreb
- Novo Nordisk Investigational Site - Bron
- Novo Nordisk Investigational Site - Nantes
- Novo Nordisk Investigational Site - Rennes
- Novo Nordisk Investigational Site - Berlin
- Novo Nordisk Investigational Site - Duisburg
- Novo Nordisk Investigational Site - Homburg
- Novo Nordisk Investigational Site - Tel Litwinsky
- Novo Nordisk Investigational Site - Kuala Lumpur
California
- Novo Nordisk Investigational Site - Torrance
Indiana
- Novo Nordisk Investigational Site - Indianapolis
Iowa
- Novo Nordisk Investigational Site - Iowa City
Maryland
- Novo Nordisk Investigational Site - Baltimore
New York
- Novo Nordisk Investigational Site - New York
Oregon
- Novo Nordisk Investigational Site - Portland
Texas
- Novo Nordisk Investigational Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-09-10 |
| Est. Completion | 2016-10-14 |
| Phase | Phase 1 |
What the finished NCT02490787 record still lists
NCT02490787 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 222-participant average among 8 other Haemophilia A trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Haemophilia A appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02490787 names 20 study sites across 11 states, led by Other, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT02490787 about?
NCT02490787 is a clinical study titled "Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects". This trial is conducted globally. The aim of this trial is to investigate safety, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of concizumab administered subcutaneously to haemophilia A subjects.
What is the current status of trial NCT02490787?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-09-10. Estimated completion is 2016-10-14.
What conditions does trial NCT02490787 study?
This clinical trial studies the following conditions: Haemophilia A, Congenital Bleeding Disorder.
What interventions are being tested in trial NCT02490787?
The interventions under investigation include: placebo (DRUG), Concizumab (DRUG).
Who is sponsoring clinical trial NCT02490787?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02490787 being conducted?
This trial has 20 study locations across California, Indiana, Iowa, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Haemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02490787's enrollment target sits among peer trials
24 8th of 8 higher than 1 of 8 other Haemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Haemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
RECRUITING · Phase 1
-
A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People
RECRUITING · Phase 1
-
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
RECRUITING
-
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
COMPLETED · Phase 3
-
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI